semaj83/ctmatch_classification huggingface dataset:
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Menstrual Cycle Perioperative Hypertension Anxiety The study included 80 women with ASA I-II Aged 18 to 45 years, who were accepted to participate in the study were smoking did not use oral contraceptives had no menstrual irregularity (regular 28 ± 2 days menstrual cycle)  In preop evaluation patients had difficulties in communication amenorrhea pregnancy delirium psychological illness major depressive disorder patients with a history of acute illness (such as in intensive care unit follow-up) which may affect cognitive function and daily life activities in the last 6 months malignancy acute renal failure
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Menstrual Cycle Cognitive Function Recovery General Anesthesia The study included 80 women with ASA I-II Aged 18 to 45 years, who were accepted to participate in the study were smoking did not use oral contraceptives had no menstrual irregularity (regular 28 ± 2 days menstrual cycle)  In preop evaluation patients had difficulties in communication amenorrhea pregnancy delirium psychological illness major depressive disorder patients with a history of acute illness (such as in intensive care unit follow-up) which may affect cognitive function and daily life activities in the last 6 months malignancy acute renal failure
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Smoking Cessation Hong Kong residents aged 18 to 65 years have used any tobacco products in the past month able to read and speak Chinese have not used NRT for the past month  Have severe angina, serious cardiac arrhythmias and hypertension Have suffered from acute myocardial event in the past 4 weeks Pregnant nor breastfeeding Under medication and treatment due to mental illness One of the was "smoke 10 cigarettes or more per day in the past week" and is amended to "have used any tobacco products in the past month". The initial intention of setting the of at least 10 cigarettes per day (CPD) is to recruit smokers who have moderate to strong level of craving and a greater need for NRT. However, we also recognize that one of the objectives of the research is to promote the use of NRT for quit attempts with NRT sampling. In fact, smokers who smoke less than 10 CPD can also benefit from using NRT gums. Therefore, the change in the does not deviate from our research aim. In contrast, with the removal of the criterion for CPD, we will be able to reach out to a larger group of smoking population and encourage more smokers to use NRT to quit smoking
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Diabetes Mellitus, Type 2 Informed consent obtained before any study-related activities. Study-related activities are any procedures related to recording of data according to the protocol The decision to initiate treatment with commercially available insulin Ryzodeg® has been made by the patient/legally acceptable representative and the treating physician before and independently from the decision to the patient in this study Male or female, age more than or equal to 20 years (the legal age of adulthood) at the time of signing informed consent Diagnosed with type 2 diabetes (T2D) for at least 26 weeks prior to signing informed consent Available and documented glycosylated haemoglobin (HbA1c) value less than or equal to 12 weeks prior to initiation of Ryzodeg® treatment For at least 26 weeks prior to initiation of Ryzodeg® treatment, one of the following must apply: A) Treated with insulin glargine (IGlar) (any formulation, including biosimilar IGlar). B) Treated with IGlar (any formulation, including biosimilar IGlar) and IGlar U300 for at least 12 weeks prior to initiation of Ryzodeg®  Previous participation in this study. Participation is defined as signed informed consent Pregnancy Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation Hypersensitivity to Ryzodeg® or to any of the excipients Previously treated with Ryzodeg®
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-30.0,  Ligament Injury Ligament; Laxity Tendon Rupture Tendon Injuries • Regular menstrual cycle (~1 x month) Not using oral contraceptive No history of serious knee injury (e.g. ACL rupture) Not currently pregnant (known) Not routinely taking medication or supplements that would interact with study measures or be contraindicated (e.g. steroid injections)  • Irregular menstrual cycling (1 x month) Using oral contraceptive History of serious knee injury (e.g. ACL rupture) Currently pregnant or potential of being pregnant Routinely taking medication or supplements that would interact with study measures or be contraindicated (e.g. steroid injections)
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Postoperative Pain Pregnant women at least 18 years of age 2. Gestational age > or = to 30 weeks 3. Singleton gestation 4. Women undergoing a non-emergent cesarean delivery 5. Spinal anesthesia or combined spinal-epidural anesthesia utilized during cesarean 6. Ability to undergo the informed consent process in English  Vertical skin incision 2. General anesthesia for cesarean 3. History of major depression or postpartum depression requiring medication 4. Chronic opiate use during pregnancy, defined as anyone who has taken an opioid or opioid replacement therapy in the 3 days prior to admission for delivery. This does not opioids given for labor anesthesia. 5. Magnesium sulfate treatment postpartum 6. Preexisting fibromyalgia, chronic pain syndrome, or rheumatologic disorder
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Tonsillectomy Pain PONV Bleeding Signed informed consent Age over 12 years Planned for elective bilateral tonsillectomy  • Insulin dependent diabetes mellitus NSAID or corticosteroid intolerance Pregnancy Gastric ulcer Immunodeficiency Treatment for chronic pain Psychiatric disorders
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Latent Tuberculosis Age 18 years + 1 day (defined as date of birth plus one day). This age cutoff has been selected as tstin3d.com has only been validated for this age group. Subjects must have all of the following Untreated Latent Tuberculosis Infection (LTBI), defined as positive Tuberculin skin test/QuantiFERON TB Gold test or T-spot assay done within 1 month prior to enrollment Absence of active TB disease as determined by history, physical examination, chest X-ray, (sputum smear and/or culture done as needed by the assessing physician for Mtb) Greater than 10% cumulative risk of developing active TB disease (determined by TSTin3D.com)  A subject will be excluded if any of the following are met Presence of active TB disease BMI <16 Cardiovascular instability (Blood pressure: Systolic >180 or <90 mm/Hg or Diastolic >100 or < 50mm/Hg; pulse <40 or >110) Chest X-Ray report within last 3 months not available HIV positive and currently on treatment with a regimen that has severe drug interactions with 3HP Presumed infected with INH or Rifapentine (RIF)-resistant M. tuberculosis Women who are pregnant, nursing or expect to become pregnant for the duration of the study Temperature ≥38.5°C or other clinical evidence of an acute infection at screening History of treatment for >14 consecutive days with a rifamycin or >30 consecutive days with isoniazid during the previous 2 years
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Pregnancy Preterm Labor; Irregular Preterm Labor Pregnant One living fetus Experiencing frequent uterine contractions  Cervical dilation > 4 cm Ruptured membranes Maternal or fetal indications for immediate delivery
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus, Type 2 Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol) Male or female, age greater than or equal to 18 years at the time of signing informed consent Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of signing the informed consent  Previous participation in this study. Participation is defined as having given informed consent in this study Diagnosed with Type 1 diabetes Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation Patients with known congenital heart disease/malformation
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Stress Urinary Incontinence Vaginal Agenesis midurethral sling procedure for stress urinary incontinence woman with vaginal agenesis  Nil
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 35.0-75.0,  Renal Transplantation Aging are group specific. HBV, HCV and HIV testing are not necessary in the RT groups as all RT recipients are tested prior to transplant. The investigators will not restrict volunteers with respect to gender, ethnic or racial group. Groups 1 (65-75 yrs) and 2 (35-45 yrs) Renal Transplant populations End stage renal disease cause either DM2 and/or hypertension (HTN) Renal transplant >12 months ago Group 3: Diabetic/hypertensive 65-75 year old controls With DM2 and/or HTN Previous immunization with PPV23 >1 year prior Willingness to be tested for HIV, HBV and HCV "normal kidney function" defined as glomerular filtration rate (GFR) of 60% or above Group 4: Healthy Control 65-75 yr old Without DM2 May have high blood pressure (systolic>140 and/or diastolic>90) as long as it is well controlled (systolic<140 and/or diastolic <90) and has not affected kidney function Previous receipt of PPV23 > 1 year prior  are either applicable to all groups or group specific. Therefore we have listed the applicable to ALL groups first. Group specific are listed under each group common to all groups Previous immunization with PCV13 Pregnancy, no contraceptive practice in women of childbearing age, or breastfeeding Known anaphylaxis, hypersensitivity or "bad allergic reaction" to the pneumonia vaccine. This does not egg allergy or previous Guillan Barre syndrome Those who received blood products or gamma globulin within 3 months Inability to comprehend or sign the informed consent form Previous/present illness that may affect immune response to the vaccine previous pneumococcal disease
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus, Type 2 Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol) Male or female, age more than or equal to 18 years at the time of signing informed consent (in Algeria more than or equal to 19 years; in Japan more than or equal to 20 years) Diagnosed with T2DM more than or equal to 180 days prior to the day of signing the informed consent  Previous participation in this study. Participation is defined as having given informed consent in this study Diagnosed with Type 1 diabetes Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation Patients with known congenital heart disease/malformation
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Healthy Key Age 18 to 65 years, inclusive Body mass index of 18.5 to 29.9 kg/m2, inclusive In good health, at the discretion of the investigator, as determined by: medical history, physical examination, vital sign assessment (specifically, blood pressure must be within normal reference range), 12-lead ECG, clinical laboratory evaluations, aspartate aminotransferase and alanine aminotransferase not above the upper limit of normal (Gilbert's syndrome is not acceptable) Female subjects of childbearing potential must be willing to use a highly effective form of birth control in conjunction with a barrier method of contraception throughout the trial and for at least 90 days after final follow-up Male subjects with a female partner of childbearing potential must be willing to use a highly effective form of birth control in conjunction with male barrier method of contraception (i.e. male condom with spermicide) throughout the trial and for at least 90 days after final follow-up. Key  Systemic or topical treatment within 14 days prior to first dose administration unless in the opinion of the investigator the medication will not interfere with the trial procedures or compromise safety Any medications, including St. John's wort, known to chronically alter drug absorption or elimination processes within 30 days prior to first dose administration Subjects who smoke more than an average of 10 cigarettes per day History of chronic alcohol or drug abuse within 12 months prior to screening Subjects with ≥3 bowel movements per day Any disorder which is not stable and could: Affect the safety of the subject throughout the trial; Influence the findings of the trial; Impede the subject's ability to complete the trial. Examples but are not limited to cardiovascular, GI, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, immunological, and psychiatric disorders and major physical impairment
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Surgical Site Infection Surgical Wound Infection Surgery--Complications Surgery Patients undergoing colorectal, hepatobiliary, upper GI, urological, vascular, or gynaecological operations Patients undergoing abdominal operations (open or laparoscopic extraction site) with a planned incision of at least 5cm Patients aged 16 years or older Patients able and willing to give written informed consent All contamination strata, including clean, clean-contaminated, contaminated or dirty surgery Patients undergoing planned (elective or expedited) or unplanned (emergency) surgery  Previous laparotomy within 3 months prior to randomisation Patients with a new or documented allergy/ intolerance to any of the study interventions (chlorhexidine, iodine, collagen or gentamicin) will not be randomised to an arm containing this intervention, but will still be eligible for recruitment to other arms of the study Patients with end-stage renal failure where gentamicin administration would otherwise be contra-indicated (according to local policy) will not be randomised to arms containing the gentamicin-impregnated sponge
Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Pain Management Any patient undergoing laparoscopic hysterectomy Benign indications Dr. Jamal Mourad or Dr. Nichole Mahnert will be performing hysterectomy  Non-English speakers History of chronic opioid use History of epilepsy History of claustrophobia Have received a prescription or taken opioids within 2 weeks for their scheduled surgery